Published in J Clin Invest on July 01, 2011
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer (2013) 4.02
Heterogeneity in breast cancer. J Clin Invest (2011) 2.86
XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway. Nature (2014) 2.84
Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov (2014) 2.55
Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol (2012) 2.46
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature (2016) 1.95
Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice. Gastroenterology (2014) 1.85
Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A (2015) 1.85
Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res (2013) 1.80
STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal (2014) 1.79
Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res (2013) 1.67
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med (2012) 1.65
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia (2013) 1.58
Acceleration of the glycolytic flux by steroid receptor coactivator-2 is essential for endometrial decidualization. PLoS Genet (2013) 1.56
Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci U S A (2014) 1.43
Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology (2014) 1.35
GLI1 regulates a novel neuropilin-2/α6β1 integrin based autocrine pathway that contributes to breast cancer initiation. EMBO Mol Med (2013) 1.33
STAT1 and STAT3 in tumorigenesis: A matter of balance. JAKSTAT (2012) 1.27
A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget (2011) 1.26
STAT3 and epithelial-mesenchymal transitions in carcinomas. JAKSTAT (2014) 1.24
Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem (2013) 1.24
STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol (2013) 1.19
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol (2016) 1.18
WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol Med (2013) 1.17
STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res (2014) 1.17
Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue. Ann N Y Acad Sci (2012) 1.17
Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention. Cancers (Basel) (2014) 1.17
Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov (2012) 1.16
Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci (2012) 1.15
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget (2015) 1.15
Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. J Biol Chem (2013) 1.15
Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev (2012) 1.15
Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res (2013) 1.13
Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene (2014) 1.11
VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene (2014) 1.10
STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6. Mol Cell Biol (2013) 1.09
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med (2014) 1.09
Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer. Neoplasia (2014) 1.07
Characterization of macrophage--cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer. Sci Rep (2015) 1.06
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin Cancer Res (2013) 1.06
Targeting Akt3 signaling in triple-negative breast cancer. Cancer Res (2013) 1.06
The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Oncogene (2014) 1.05
SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene (2014) 1.04
Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation. Oncogene (2015) 1.04
Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. Mol Cell Endocrinol (2013) 1.04
Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition. PLoS One (2013) 1.02
S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer. Mol Cancer Res (2012) 1.01
Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. Cancer Prev Res (Phila) (2012) 1.01
HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s. Clin Cancer Res (2013) 1.00
Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest (2014) 1.00
Surgery-induced wound response promotes stem-like and tumor-initiating features of breast cancer cells, via STAT3 signaling. Oncotarget (2014) 0.99
Targeting autophagy in breast cancer. World J Clin Oncol (2014) 0.99
A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway. Oncotarget (2015) 0.99
High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano (2013) 0.98
Balancing the innate immune system in tumor development. Trends Cell Biol (2014) 0.98
Regulation of breast cancer stem cell features. Contemp Oncol (Pozn) (2015) 0.97
Constitutive activation of STAT3 signaling regulates hTERT and promotes stem cell-like traits in human breast cancer cells. PLoS One (2013) 0.96
Bone marrow endothelium-targeted therapeutics for metastatic breast cancer. J Control Release (2014) 0.96
Constitutive activation of STAT3 in breast cancer cells: A review. Int J Cancer (2015) 0.96
Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis. Mol Oncol (2014) 0.96
Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS One (2013) 0.96
Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy. Cancer Sci (2015) 0.94
Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. J Clin Invest (2013) 0.94
Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model. PLoS One (2013) 0.94
EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene (2013) 0.94
Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines. Int J Breast Cancer (2013) 0.94
Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. J Clin Invest (2014) 0.94
Pancreatic cancer stem cell biology and its therapeutic implications. J Gastroenterol (2011) 0.93
Endothelial interleukin-6 defines the tumorigenic potential of primary human cancer stem cells. Stem Cells (2014) 0.93
Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget (2014) 0.93
Autophagy Supports Breast Cancer Stem Cell Maintenance by Regulating IL6 Secretion. Mol Cancer Res (2015) 0.93
Long noncoding RNA lncTCF7, induced by IL-6/STAT3 transactivation, promotes hepatocellular carcinoma aggressiveness through epithelial-mesenchymal transition. J Exp Clin Cancer Res (2015) 0.93
How should we define STAT3 as an oncogene and as a potential target for therapy? JAKSTAT (2013) 0.93
Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer. Oncotarget (2015) 0.93
Hwanggeumchal sorghum induces cell cycle arrest, and suppresses tumor growth and metastasis through Jak2/STAT pathways in breast cancer xenografts. PLoS One (2012) 0.93
STAT3 in Cancer-Friend or Foe? Cancers (Basel) (2014) 0.93
Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents. Mol Cancer Ther (2013) 0.92
Enhanced enrichment of prostate cancer stem-like cells with miniaturized 3D culture in liquid core-hydrogel shell microcapsules. Biomaterials (2014) 0.91
Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep (2015) 0.91
Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers. Genes Dev (2015) 0.91
Cancer-linked targets modulated by curcumin. Int J Biochem Mol Biol (2012) 0.91
Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesis. Cell Death Differ (2013) 0.91
Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors. Proc Natl Acad Sci U S A (2014) 0.91
Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer. Oncotarget (2014) 0.91
CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis. Mol Cancer Ther (2015) 0.90
Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner. Mol Cancer Res (2012) 0.90
Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation. BMC Cancer (2014) 0.90
Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. Cancer Med (2013) 0.90
Regulation of cancer stem cell activities by tumor-associated macrophages. Am J Cancer Res (2012) 0.90
ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat Commun (2016) 0.90
A mammosphere formation RNAi screen reveals that ATG4A promotes a breast cancer stem-like phenotype. Breast Cancer Res (2013) 0.89
Evaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells. PLoS One (2013) 0.89
Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling. PLoS One (2013) 0.89
Primary breast cancer stem-like cells metastasise to bone, switch phenotype and acquire a bone tropism signature. Br J Cancer (2013) 0.88
Modulation of STAT3 folding and function by TRiC/CCT chaperonin. PLoS Biol (2014) 0.88
Genetics of breast cancer bone metastasis: a sequential multistep pattern. Clin Exp Metastasis (2014) 0.87
Posttranscriptional regulation of PER1 underlies the oncogenic function of IREα. Cancer Res (2013) 0.87
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Sci Transl Med (2016) 0.86
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat Commun (2015) 0.86
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell (2009) 10.09
Cancer as an evolutionary and ecological process. Nat Rev Cancer (2006) 9.33
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature (2007) 7.55
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell (2009) 6.26
Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med (2006) 5.92
Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2009) 5.90
The increasing complexity of the cancer stem cell paradigm. Science (2009) 5.45
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature (2008) 5.38
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest (2007) 4.71
The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res (2008) 4.63
STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J (1999) 4.55
Aspirin intake and survival after breast cancer. J Clin Oncol (2010) 4.50
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell (2009) 4.47
Regulation of in situ to invasive breast carcinoma transition. Cancer Cell (2008) 4.46
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest (2010) 4.22
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest (2010) 4.22
Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods (2006) 4.12
Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell (2009) 3.29
The therapeutic promise of the cancer stem cell concept. J Clin Invest (2010) 3.26
Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res (2008) 3.25
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer (2006) 3.19
Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res (2010) 3.19
Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99
Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat (2006) 2.89
Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev (2008) 2.62
Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res (2006) 2.61
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell (2011) 2.56
Targeting breast cancer stem cells. J Clin Oncol (2010) 2.53
Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem (2008) 2.42
JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol (2008) 2.37
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res (2007) 2.32
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia (2007) 2.31
IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep (2009) 2.14
Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther (2008) 1.89
CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther (2008) 1.86
B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest (1997) 1.84
Menadione-induced reactive oxygen species generation via redox cycling promotes apoptosis of murine pancreatic acinar cells. J Biol Chem (2006) 1.82
Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res (2008) 1.78
Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res (2009) 1.72
CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer (2007) 1.62
Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines. J Biol Chem (2002) 1.59
STAT3 as a central regulator of tumor metastases. Curr Mol Med (2009) 1.57
Functional analysis of OMICs data and small molecule compounds in an integrated "knowledge-based" platform. Methods Mol Biol (2009) 1.31
Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord (2005) 1.30
LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell Biol (2010) 1.25
Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol Cancer Ther (2010) 1.22
The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res (2008) 1.21
Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-beta signaling. Oncogene (2008) 1.12
Purification and characterization of recombinant human prostacyclin synthase. J Biochem (2004) 0.90
Anti-interleukin-6 receptor antibody therapy in rheumatic diseases. Endocr Metab Immune Disord Drug Targets (2006) 0.89
Novel role of CXCR2 in regulation of gamma-secretase activity. ACS Chem Biol (2008) 0.86
Prostacyclin receptor induces STAT1 and STAT3 phosphorylations in human erythroleukemia cells: a mechanism requiring PTX-insensitive G proteins, ERK and JNK. Cell Signal (2005) 0.83
Model-based analysis of ChIP-Seq (MACS). Genome Biol (2008) 51.63
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Genome-wide analysis of estrogen receptor binding sites. Nat Genet (2006) 18.63
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell (2005) 14.32
FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell (2008) 14.18
Model-based analysis of tiling-arrays for ChIP-chip. Proc Natl Acad Sci U S A (2006) 13.68
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature (2011) 11.31
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
The life history of 21 breast cancers. Cell (2012) 10.59
Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project. Science (2010) 9.78
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Res (2012) 9.13
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature (2010) 8.87
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 8.38
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Differential chromatin marking of introns and expressed exons by H3K36me3. Nat Genet (2009) 8.11
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature (2011) 7.43
Model-based analysis of two-color arrays (MA2C). Genome Biol (2007) 7.28
Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci U S A (2005) 7.21
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Ductal carcinoma in situ of the breast. N Engl J Med (2004) 6.63
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science (2009) 6.07
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Nucleosome dynamics define transcriptional enhancers. Nat Genet (2010) 5.94
A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science (2011) 5.91